Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug;77(8):918-26.
doi: 10.1136/jnnp.2006.090365. Epub 2006 May 11.

Costs and quality of life of patients with multiple sclerosis in Europe

Affiliations

Costs and quality of life of patients with multiple sclerosis in Europe

G Kobelt et al. J Neurol Neurosurg Psychiatry. 2006 Aug.

Abstract

Objective: To assess overall resource consumption, work capacity and quality of life of patients with multiple sclerosis in nine European countries.

Methods: Information on resource consumption related to multiple sclerosis, informal care by relatives, productivity losses and overall quality of life (utility) was collected with a standardised pre-tested questionnaire from 13,186 patients enrolled in national multiple sclerosis societies or followed up in neurology clinics. Information on disease included disease duration, self-assessed disease severity and relapses. Mean annual costs per patient (Euro, 2005) were estimated from the societal perspective.

Results: The mean age ranged from 45.1 to 53.4 years, and all levels of disease severity were represented. Between 16% and 29% of patients reported experiencing a relapse in the 3 months preceding data collection. The proportion of patients in early retirement because of multiple sclerosis ranged from 33% to 45%. The use of direct medical resources (eg, hospitalisation, consultations and drugs) varied considerably across countries, whereas the use of non-medical resources (eg, walking sticks, wheel chairs, modifications to house and car) and services (eg, home care and transportation) was comparable. Informal care use was highly correlated with disease severity, but was further influenced by healthcare systems and family structure. All types of costs increased with worsening disease. The total mean annual costs per patient (adjusted for gross domestic product purchasing power) were estimated at Euro 18,000 for mild disease (Expanded Disability Status Scale (EDSS) <4.0), Euro 36,500 for moderate disease (EDSS 4.0-6.5) and Euro 62,000 for severe disease (EDSS >7.0). Utility was similar across countries at around 0.70 for a patient with an EDSS of 2.0 and around 0.45 for a patient with an EDSS of 6.5. Intangible costs were estimated at around Euro 13,000 per patient.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Parkin D, Jacoby A, McNamee P. Treatment of multiple sclerosis with interferon beta‐1b: an appraisal of cost‐effectiveness and quality of life. J Neurol Neurosurg Psychiatry 200068144–149. - PMC - PubMed
    1. Forbes R B, Lees A, Waugh N.et al Population based cost utility study of interferon beta‐1b in secondary progressive multiple sclerosis. BMJ 19993191529–1533. - PMC - PubMed
    1. Kobelt G, Jönsson L, Henriksson F.et al Cost‐utility of interferon beta‐1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 200016768–780. - PubMed
    1. Kobelt G, Jönsson L, Miltenburger C. Cost‐utility analysis of interferon‐beta‐1b in secondary progressive multiple sclerosis, using natural history disease data. Int J Technol Assess Health Care 200218127–138. - PubMed
    1. Kobelt G, Jönsson L, Fredrikson S. A new disease model to estimate the cost of disease progression for different types of MS and different subgroups of patients. Eur J Health Econ 2003450–59. - PubMed

Publication types